Prolonged Survival of Thymomabearing Mice after Vaccination with a Soluble Protein Antigen Entrapped in Liposomes: A Model Study

Cancer Research

Volumn 52, Issue 22, 1992, Pages 6287-6291

  Zhou, Fan ^a,b   Rouse, Barry T ^a   Huang, Leaf ^a,b  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; COMPLEMENTARY DNA; LIPOSOME;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ANTIGEN FUNCTION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CHICKEN; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMOMA; VACCINATION;

ANIMAL; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; EPITOPES; FEMALE; LIPOSOMES; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; OVALBUMIN; SPLEEN; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES, CYTOTOXIC; THYMOMA; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0026442140     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Herberman, R. B., Reynolds, C. W., and Ortaldo, J. R. Mechanism of cytotoxicity by natural killer (NK) cells. Annu. Rev. Immunol., 4:651-680,1986.
2. Evans, R. The immunology network at the site of tumor rejection. Biochim. Biophys. Acta, 865: 1-11, 1986.
3. Rosenberg, S. A., and Lotze, M. T. Cancer immunotherapy using IL-2 and 1L-2 activated lymphocytes. Annu. Rev. Immunol., 4: 681-709, 1986.
4. Rosenberg, S. A., Spiess, P. J., and Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science (Washington DC), 233: 1318-1321, 1986.
5. Greenberg, P. D. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia. J. Immunol., 136: 1917-1922, 1986.
6. HarelBellam, A., Quillet, A., Marchiol, C., DeMars, R., Tursz, T., and Fradelizi, D. Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6. Proc. Natl. Acad. Sci. USA, 83: 5688-5692, 1986.
7. Cheever, M. A., Greenberg, P. D., and Fefer, A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J. Immunol., 125: 711-714, 1980.
8. Cheever, M. A., Greenberg, P. D., Fefer, A., and Gillis, S. Augmentation of the anti-tumor therapeutic efficacy of long term cultured T lymphocytes by in vivo administration of purified IL-2. J. Exp. Med., 155: 968-980, 1982.
9. Fan, S. T., and Edgington, T. S. Sufficiency of the CD8+ T lymphocytes to mount an effective tumoricidal response to syngeneic tumor-bearing novel class I MHC antigen. J. Immunol., 143:4287-4291, 1989.
10. Hoover, H. C., Surdyke, M. G., Dangel, R. B., Peters, L. C., and Hanna, M. G. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer (Phila.), 15: 1236-1243, 1985.
11. Talarico, D., Ittmann, M., Belsari, A., DelliBori, P., Basch, R. S., and Basilico, C. Protection of mice against tumor growth by immunization with an oncogeneencoded growth factor. Proc. Natl. Acad. Sci. USA, 87:4222-4225, 1990.
12. Carbone, F. R., and Bevan, M. J. Class I-restricted processing and presentation of exogenous cell associated antigen in vivo. J. Exp. Med., 171: 377-387, 1990.
13. Harding, C. V., Collins, D. S., Slot, J. W., Geuze, H. J., and Unanue, E. R. Liposome-encapsulated antigens are processed in lysosomes, recycled, and presented to T cells. Cell, 64: 393-401, 1991.
14. Deres, K., Schild, H., Wiesmuller, K-H., Jung, G., and Rammensee, H. G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccines. Nature (Lond.), 342: 561-564, 1989.
15. Takahashi, H., Takeshita, T., Morein, B., Putney, S., Germain, R. N., and Berzofsky, J. A. Induction of CD8+ cytotoxic T lymphocytes by immunization with purified HIV-1 envelope proteins in ISCOMs. Nature (Lond.), 344: 873-875, 1990.
16. Reddy, R., Zhou, F., Huang, L., and Rouse, B. T. pH-sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of soluble proteins. J. Immunol. Methods, 141: 157-163, 1991.
17. Zhou, F., Rouse, B. T., and Huang, L. An improved method of loading pH-sensitive liposomes with soluble proteins for class I restricted antigen presentation. J. Immunol. Methods, 145: 143-152, 1991.
18. Moore, M. W., Carbone, F. R., and Bevan, M. J. Introduction of soluble proteins into the class I pathway of antigen processing and presentation. Cell, 54: 777-785, 1988.
19. Reddy, R., Zhou, F., Nair, S., Huang, L., and Rouse, B. T. In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J. Immunol., 148: 1585-1589, 1992.
20. Holmberg, E., Maruyama, K., Litzinger, D. C., Wright, S., Davis, M., Kabalka, G. W., Kennel, S. J., and Huang, L. Highly efficient immunoliposomes prepared with a method which is comparable with various lipid compositions. Biochem. Biophys. Res. Commun., 165: 1272-1278, 1989.
21. Okada, C. Y., and Rechsteiner, M. Introduction of macromolecules into the cultured mammalian cells by osmotic lysis of pinosome vesicles. Cell, 29: 33-41, 1982.
22. Collins, D., and Huang, L. Immunoliposomes with different acid sensitivities as probes for the cellular endocytic pathway. Biochim. Biophys. Acta, 987: 27-53, 1989.
23. Nair, S., Zhou, F., Reddy, R., Huang, L., and Rouse, B. T. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte response in vitro. J. Exp. Med. 175:609-612, 1992.
24. van Rooijen, N. Liposomes as immunological adjuvants: recent developments. In: G. Gregoriadis (ed.), Liposomes as Drug Carriers, pp. 159-164. John Wiley and Sons, Chichester, UK, 1988.
25. Storkus, W. J., Alexander, J., Payne, J. A., Downson, J. R., and Cresswell, P. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA, 86:2361-2364,1989.
26. Roerdink, F., Dijkstra, J., Hartman, G., Bolscher, B., and Scherphof, G. The involvement of parenchymal, Kupffer and endothelial liver cells in the hepatic uptake of intravenously injected liposomes. Biochim. Biophys. Acta, 677: 79-89, 1981.
27. Fidler, I. J. Systemic macrophage activation with liposome entrapped immunomodulators for therapy of cancer metastases. Res. Immunol., 143: 199-204, 1992.
28. van Rooijen, N., Kors, N. V. D. Ende, M., and Dijkstra, C. D. Depletion and repopulation of macrophages in the spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate. Cell Tissue Res., 260: 215-222, 1990.
29. Zhou, F., Rouse, B. T., and Huang, L. Induction of cytotoxic T lymphocytes in vivo with antigen entrapped in membranous vehicles. J. Immunol., 149: 1599-1664, 1992.